Conditions: Hypoglycemia
Keywords: Hypoglycemia Glucagon Diabetes
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 13
Healthy volunteers: no

Brief summary:
The purpose of the study is to demonstrate that mini-doses of stable liquid glucagon (G-Pen Mini) produced by Xeris Pharmaceuticals are safe and effective as a treatment for mild to moderate hypoglycemia, a complication of diabetes.

Detailed description:

Arms:
arm 1: G-Pen Mini™ (glucagon injection), two 75 microgram subcutaneous injections given approximately 4-5 hours apart arm 2: G-Pen Mini™ (glucagon injection), two 150 microgram subcutaneous injections given approximately 4-5 hours apart arm 3: G-Pen Mini™ (glucagon injection), two 300 microgram subcutaneous injections given approximately 4-5 hours apart

Interventions: intervention 1: G-Pen Mini™ (glucagon injection)
Intervention descriptions: intervention 1: stable, pre-mixed, liquid glucagon for subcutaneous injection

Protocol document: